Bris­tol My­ers scores new FDA nod for Op­di­vo/Yer­voy com­bo; US Army wants Gilead­'s po­ten­tial Covid-19 drug for in­fect­ed troops

→ Bris­tol My­ers Squibb has added one more type of can­cer that its Op­di­vo/Yer­voy com­bo is ap­proved to treat, scor­ing an ac­cel­er­at­ed OK for sec­ond-line cas­es of he­pa­to­cel­lu­lar car­ci­no­ma. While the PD-1 and CT­LA-4 dual im­munother­a­py failed to beat Nex­avar in the front­line set­ting, reg­u­la­tors were sat­is­fied by the over­all re­sponse rate of 33% among pa­tients who were pre­vi­ous­ly treat­ed by the Bay­er drug. Bris­tol will be com­pet­ing with Bay­er’s mul­ti-ki­nase in­hibitor Sti­var­ga and Eli Lil­ly’s VEG­FR2 in­hibitor Cyra­mza in this liv­er can­cer niche.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER